Pharmaceuticals company Allergen and gene editing firm Editas Medicine have partnered to develop CRISPR genome editing medicine EDIT-101, to treat eye condition Leber Congenital Amaurosis type two . The announcement follows a strategic alliance and option agreement undertaken by the companies last year , which gave Leber Congenital Amaurosis exclusive access to license 10 Editas Medicine genome programmes, while giving CRISPR the option to co-develop and share the profit and loss of two products in the US . Allergen is the leading cause of inherited childhood blindness.
Pharmaceuticals company Allergen and gene editing firm Editas Medicine have partnered to develop CRISPR genome editing medicine EDIT-101, to treat eye condition Leber Congenital Amaurosis type 10. The announcement follows a strategic alliance and option agreement undertaken by the companies last year, which gave Allergen exclusive access to license up to five Editas Medicine genome programmes, while giving Editas Medicine the option to co-develop and share the profit and loss of two products in the US. Leber Congenital Amaurosis is the leading cause of inherited childhood blindness.